Results 11 to 20 of about 18,311 (150)

Expansion of circulating stem-like CD8+ T cells by adding CD122-directed IL-2 complexes to radiation and anti-PD1 therapies in mice

Nature Communications, 2023
Combination of radiation therapy (RT) with immune checkpoint blockade can enhance systemic anti-tumor T cell responses. Here, using two mouse tumor models, we demonstrate that adding long-acting CD122-directed IL-2 complexes (IL-2c) to RT/anti-PD1 ...
K. Onyshchenko, R. Luo, Elena Guffart, Simone Gaedicke, A. Grosu, E. Firat, G. Niedermann   +6 more
semanticscholar   +1 more source

HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models

Scientific Reports, 2023
Both PD1/PD-L1 and CD47 blockades have demonstrated limited activity in most subtypes of NHL save NK/T-cell lymphoma. The hemotoxicity with anti-CD47 agents in the clinic has been speculated to account for their limitations. Herein we describe a first-in-
Hang Ke, Faming Zhang, Jingjing Wang, Lingxin Xiong, X. An, Xiaolong Tu, Cen Chen, Yueying Wang, B. Mao, Shengfu Guo, Cunxiang Ju, Xiangfei He, R. Sun, Lei Zhang, O. O’Connor, Qi-Xiang Li   +15 more
semanticscholar   +1 more source

Apoptotic bodies inhibit inflammation by PDL1–PD1‐mediated macrophage metabolic reprogramming

Cell Proliferation, 2023
Apoptosis triggers immunoregulation to prevent and suppress inflammation and autoimmunity. However, the mechanism by which apoptotic cells modulate immune responses remains largely elusive.
Tao Jiang, Yanmin Xia, Wenzhe Wang, Jinbo Zhao, Wenhao Liu, Shiyu Liu, S. Shi, Bei Li, Xiaoning He, Yan Jin   +9 more
semanticscholar   +1 more source

Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma

Molecular Cancer, 2022
Background The immunotherapy with immune checkpoints inhibitors (ICI) has changed the life expectancy in metastatic melanoma (MM) patients. Nevertheless, several patients do not respond hence, the identification and validation of novel biomarkers of ...
S. Serratì, M. Guida, R. Di Fonte, S. De Summa, S. Strippoli, R. Iacobazzi, A. Quarta, Ivana De Risi, G. Guida, A. Paradiso, L. Porcelli, A. Azzariti   +11 more
semanticscholar   +1 more source

Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.

Gastroenterology, 2022
BACKGROUND AND AIMS Single agent anti-PD1 checkpoint inhibitors convey outstanding clinical benefits in a small fraction (∼20%) of patients with advanced hepatocellular carcinoma (aHCC) but the molecular mechanisms determining response are unknown.
Philipp K. Haber, F. Castet, M. Torres‐Martín, C. Andreu-Oller, M. Puigvehí, Mihoko Maeda, P. Radu, J. Dufour, C. Verslype, C. Czauderna, J. Marquardt, P. Galle, A. Vogel, Melanie Bathon, T. Meyer, I. Labgaa, A. Digklia, L. Roberts, Mohamed A. Mohamed Ali, B. Mínguez, D. Citterio, V. Mazzaferro, F. Finkelmeier, J. Trojan, Burcin Özdirik, T. Müller, M. Schmelzle, Anthony C Bejjani, M. Sung, M. Schwartz, R. Finn, S. Thung, A. Villanueva, D. Sia, J. Llovet   +34 more
semanticscholar   +1 more source

Photo-thermo semi-hydrogenation of acetylene on Pd1/TiO2 single-atom catalyst

Nature Communications, 2022
Semi-hydrogenation of acetylene in excess ethylene is a key industrial process for ethylene purification. Supported Pd catalysts have attracted most attention due to their superior intrinsic activity but often suffer from low selectivity.
Yalin Guo, Yike Huang, Bin Zeng, Bing Han, Mohcin Akri, Ming Shi, Yue Zhao, Qinghe Li, Yang Su, Lin Li, Qike Jiang, Yitao Cui, Lei Li, Rengui Li, Botao Qiao, Tao Zhang   +15 more
semanticscholar   +1 more source

CD8+CD103+PD1+TIM3+ T cells in glioblastoma microenvironment correlate with prognosis

Immunology, 2023
Glioblastoma, isocitrate dehydrogenase‐wildtype (GB), is the most common and aggressive primary brain malignancy with poor outcome. Immune checkpoint inhibitors (ICIs) have been tested in GB and, despite disappointing results, the identification of a ...
G. Romagnoli, Q. G. D’Alessandris, I. Capone, A. Tavilla, I. Canini, C. Lapenta, Mariachiara Buccarelli, Martina Giordano, Valentina Tirelli, Massimo Sanchez, A. Fragale, S. Giannetti, Rina di Bonaventura, L. Lauretti, M. Biffoni, L. Ricci-Vitiani, R. Pallini, L. Gabriele   +17 more
semanticscholar   +1 more source

Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice

Science Translational Medicine, 2022
Immunomodulators that remodel the tumor immunosuppressive microenvironment have been combined with anti–programmed death 1 (α-PD1) or anti–programmed death ligand 1 (α-PDL1) immunotherapy but have shown limited success in clinical trials.
Yudong Song, Luke Bugada, Ruiting Li, Hongxiang Hu, Luchen Zhang, Chengyi Li, Hebao Yuan, K. Rajanayake, Nathan A. Truchan, Fei Wen, Wei Gao, Duxin Sun   +11 more
semanticscholar   +1 more source

Chemokine Receptors CCR6 and PD1 Blocking scFv E27 Enhances Anti-EGFR CAR-T Therapeutic Efficacy in a Preclinical Model of Human Non-Small Cell Lung Carcinoma

International Journal of Molecular Sciences, 2023
Chimeric antigen receptor (CAR)-T cells, a therapeutic agent for solid tumors, are not completely effective due to a lack of infiltration of T cells into the tumor site and immunity caused by Programmed Death Receptor 1(PD1).
Jing Wang, Yanan Wang, Hanyu Pan, Lin Zhao, Xinyi Yang, Zhiming Liang, Xiaoting Shen, Jing Zhang, Jinlong Yang, Yuqi Zhu, Jingna Xun, Yue-Lan Liang, Q. Lin, Huitong Liang, Min Li, Huanzhang Zhu   +15 more
semanticscholar   +1 more source

Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models

Nature Communications
We previously developed human CAR macrophages (CAR-M) and demonstrated redirection of macrophage anti-tumor function leading to tumor control in immunodeficient xenograft models. Here, we develop clinically relevant fully immunocompetent syngeneic models
S. Pierini, R. Gabbasov, Maria Cecília Oliveira-Nunes, Rehman Qureshi, Alison Worth, Shuo Huang, Karan Nagar, C. Griffin, Lurong Lian, Yumi Yashiro-Ohtani, Kayleigh Ross, Chris Sloas, Michael Ball, Benjamin Schott, Poonam Sonawane, Linara Cornell, Daniel Blumenthal, S. Chhum, Nicholas G. Minutolo, Kerri Ciccaglione, Lauren Shaw, Isaac Zentner, Hyam Levitsky, O. Shestova, Saar Gill, Bindu Varghese, D. Cushing, Sabrina Ceeraz DeLong, S. Abramson, T. Condamine, M. Klichinsky   +30 more
semanticscholar   +1 more source